These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27461600)

  • 1. SiRNA and epigenetic aberrations in ovarian cancer.
    Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
    J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in ovarian cancer.
    Seeber LM; van Diest PJ
    Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation of cancer-associated genes in ovarian cancer.
    Kwon MJ; Shin YK
    Int J Mol Sci; 2011 Jan; 12(2):983-1008. PubMed ID: 21541038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA delivery for the treatment of ovarian cancer.
    Goldberg MS
    Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation.
    Leu YW; Rahmatpanah F; Shi H; Wei SH; Liu JC; Yan PS; Huang TH
    Cancer Res; 2003 Oct; 63(19):6110-5. PubMed ID: 14559786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
    Malek A; Tchernitsa O
    Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells.
    Lin Y; Cui M; Xu T; Yu W; Zhang L
    Mol Med Rep; 2014 Jun; 9(6):2499-504. PubMed ID: 24718658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Barton CA; Hacker NF; Clark SJ; O'Brien PM
    Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
    Bapat SA; Jin V; Berry N; Balch C; Sharma N; Kurrey N; Zhang S; Fang F; Lan X; Li M; Kennedy B; Bigsby RM; Huang TH; Nephew KP
    Epigenetics; 2010; 5(8):716-29. PubMed ID: 20676026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vector construction and silencing effect of Edg4 gene targeted small interfering RNA in ovarian cancer cell line].
    Qiao YH; Li LX; Guo RX; Zhou W; Wang M; Zhang XY; Zhang JH; Zhao XL; Zhang MZ; Zhao GQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):765-9. PubMed ID: 18307905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
    Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
    J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
    Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
    Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minireview: epigenetic changes in ovarian cancer.
    Balch C; Fang F; Matei DE; Huang TH; Nephew KP
    Endocrinology; 2009 Sep; 150(9):4003-11. PubMed ID: 19574400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
    Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
    SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.